IL17A and candidiasis: While rare, these genetic disorders lend persuasive evidence for the critical role of the Th17/IL-17 pathway in control of Candida infections especially at mucosal surfaces, and supports the concerns raised regarding the clinical use of anti-IL-17/IL-17R antibody therapies (see below) [65,87].